Sitaphage Xr (50/500) mg Tablets 14s
Sitagliptin and metformin XR 50/500mg for type 2 diabetes.
Sitaphage Xr (50/500) mg combines sitagliptin (DPP-4 inhibitor) and metformin in extended-release formulation for type 2 diabetes. Used when dual therapy is needed. Take once or twice daily with meals as directed; swallow whole.
Purpose
Treatment of type 2 diabetes mellitus as adjunct to diet and exercise when dual therapy is appropriate.
Ingredients
Sitagliptin 50mg and metformin hydrochloride 500mg (extended-release) per tablet.
Warnings
Contraindicated in severe renal impairment and diabetic ketoacidosis. Not for type 1 diabetes. Risk of lactic acidosis with metformin.
Side Effects
Nausea, diarrhoea, abdominal discomfort, hypoglycaemia when combined with insulin or sulphonylurea. Rare: pancreatitis. Report severe abdominal pain.
Storage Instructions
Store below 30°C in a dry place. Keep in original pack; protect from moisture.
| Brand | Martin DOW |
| Status | Active |
Related Products
